AssetMark Inc’s Indivior Pharmaceuticals INDV Stock Holding History

AssetMark Inc’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$645	Buy	+18	New	+$680	﹤0.01%	3339

Other funds holding INDV

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AssetMark Inc's INDV Position: Q3 2026 in Review

AssetMark Inc opened a new position in Indivior Pharmaceuticals (INDV) in Q3 2026: 18 shares worth $645. The stake represents ﹤0.01% of the portfolio and ranks #3339 among its holdings.

104 funds tracked by Wall St. Rank hold INDV as of Q3 2026.

AssetMark Inc held 18 shares of Indivior Pharmaceuticals worth $645 as of Q3 2026.
Indivior Pharmaceuticals was a new AssetMark Inc position in Q3 2026.
Indivior Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3339 holding.
104 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.